We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

CAROLINA LIQUID CHEMISTRIES

Carolina Liquid Chemistries offers a complete line of clinical chemistry analyzers and reagents for use on common pla... read more Featured Products: More products

Download Mobile App




Automated Glycated Hemoglobin Assay Now Certified by US Glycohemoglobin Standardization Program

By LabMedica International staff writers
Posted on 24 Jul 2014
Print article
Image: The CLC720 chemistry analyzer (Photo courtesy of the Carolina Liquid Chemistries Corporation).
Image: The CLC720 chemistry analyzer (Photo courtesy of the Carolina Liquid Chemistries Corporation).
An assay for the measurement of glycated hemoglobin (HbA1c) designed for use on a new-generation automated chemistry analyzer was recently certified by the [US] National Glycohemoglobin Standardization Program (NGSP).

HbA1c is a derivative of hemoglobin that is formed nonenzymically by reaction at the N terminus of the protein molecule with glucose. In the normal adult human such derivatives constitute a few percent of the total erythrocyte hemoglobin, the most abundant being hemoglobin A1c, which increases several fold in concentration in diabetes mellitus, and is assayed to monitor control of diabetes. Once a hemoglobin molecule is glycated, it remains that way. A buildup of glycated hemoglobin within the red cell, therefore, reflects the average level of glucose to which the cell has been exposed during its life-cycle. Measuring glycated hemoglobin assesses the effectiveness of therapy by monitoring long-term serum glucose regulation. The HbA1c level is proportional to average blood glucose concentration over the previous four weeks to three months.

In the United States, HbA1c testing laboratories are certified by the National Glycohemoglobin Standardization Program (NGSP) to standardize them against the results of the 1993 Diabetes Control and Complications Trial (DCCT). This landmark study showed that the risk for development and progression of the chronic complications of diabetes was closely related to the degree of glycemic control, as measured by HbA1c. The DCCT also provided a large body of data relating HbA1c values to mean blood glucose.

Carolina Liquid Chemistries Corporation (Winston-Salem, NC, USA) recently announced today that its new Hemoglobin A1c test (HbA1c-direct), designed for use on the CLC720 chemistry analyzer had been certified by the NGSP.

“There are other HbA1c tests on the market,” said Patricia Shugart, chief operating officer at Carolina Liquid Chemistries Corporation, “but our HbA1c-direct is special in two ways. First, it’s a direct test, meaning there is no manual sample pretreatment. Second, it is categorized as moderately complex, which avoids the extra cost of a high complexity lab.”

The speed and ease of HbA1c-direct is made possible by the enhanced capabilities of the CLC720 chemistry analyzer, which, unlike most analyzers in its class, automates the lysing step that would otherwise have to be performed manually.

“Our test correlates to the NGSP certified tests used in large-scale diabetes studies,” said Patricia Shugart. “Physicians can now relate their HbA1c-direct results to these studies, providing more relevance.”

Related Links:
Carolina Liquid Chemistries Corporation



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.